Product Details
COSENTYX 125MG/5ML IV SDV EA
Manufacturer: Novartis
MFG#: 00078-1168-61
NDC: 00078-1168-61
PID: 666786
1/EA
$ *.**
In StockAdditional Information
| Product Name | Cosentyx 125 Mg/5ml IV SDV Ea |
| Application | Monoclonal Antibody |
| Generic Drug Name | Secukinumab |
| Mechanism of Action | Inhibits IL-17A to reduce inflammation and immune response |
| Strength | 25 mg/mL (Total 125 mg per vial) |
| Type | Subcutaneous |
| Volume | 5 mL |
| Administration Schedule | Initial: 150 mg or 300 mg at weeks 0, 1, 2, 3, and 4; Maintenance: 150 mg or 300 mg every 4 weeks |
| Common Side Effects | Nasopharyngitis, headache, diarrhea, upper respiratory infections |
| Serious Reactions | Increased risk of infections, hypersensitivity reactions, exacerbation of inflammatory bowel disease |
| Precautions | Monitor for infections, tuberculosis screening before initiation |
| Storage Requirements | Requires Refrigeration (2°C to 8°C / 36°F to 46°F) |
| Container Type | Single-Dose Vial |
| Uses | Treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis |
Description
Cosentyx (125 mg SDV, 5 mL) is a human monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It contains secukinumab, an interleukin-17A (IL-17A) inhibitor that selectively binds to and neutralizes IL-17A, a key cytokine involved in inflammatory and immune-mediated diseases.
The injection is supplied as a sterile single-dose vial containing 125 mg of secukinumab in 5 mL of solution. It is a clear to slightly opalescent, colorless to light yellow liquid intended for subcutaneous administration. The vial should be visually inspected for particulate matter and discoloration before use.
Cosentyx is administered via subcutaneous injection. The recommended dosing regimen varies by indication, with an initial loading dose of 150 mg or 300 mg at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 150 mg or 300 mg every four weeks. Injection sites should be rotated to minimize irritation.
Frequently Asked Questions (FAQs)
The cost of COSENTYX 125MG/5ML IV SDV EA is $$0.00
COSENTYX 125MG/5ML IV SDV EA is manufactured by Novartis.
You can purchase COSENTYX 125MG/5ML IV SDV EA on our website at https://supplies.pipelinemedical.com/product/detail/cosentyx-125mg-5ml-5ml-sdv-666379